The ability to culture pluripotent stem cells and direct their differentiation into specific cell types in vitro provides a valuable experimental system for modeling pluripotency, development and cellular differentiation. High-throughput profiling of the transcriptomes and epigenomes of pluripotent stem cells and their differentiated derivatives has led to identification of patterns characteristic of each cell type, discovery of new regulatory features in the epigenome and early insights into the complexity of dynamic interactions among regulatory elements. This work has also revealed potential limitations of the use of pluripotent stem cells as in vitro models of developmental events, due to epigenetic variability among different pluripotent stem cell lines and epigenetic instability during derivation and culture, particularly at imprinted and X-inactivated loci. This review focuses on the two most well-studied epigenetic mechanisms, DNA methylation and histone modifications, within the context of pluripotency and differentiation.
Early mammalian development involves precise orchestration of gene expression in a spatial and temporal manner in order to establish cell lineage fate. Starting from a totipotent state, cells fated to the embryonic lineages pass through a pluripotent state and then branch off into the germline and the three germ cell lineages: the ectoderm, mesoderm and endoderm. Multipotent progenitor cells in these major lineages then differentiate further to produce more than 200 specialized cell types in the fully developed organism.
The differentiation process is accompanied by changes in the transcriptome, and much has been learned about the signals that govern it by performing gene expression analyses of differentiating and differentiated cells. Such experiments have demonstrated the critical role that transcription factors play in the regulation of temporal and spatial gene expression programs by binding to cis-regulatory regions in response to environmental cues. There is an increasing appreciation of the role of epigenetic mechanisms in the regulation of the transcriptome, and recognition that changes in the epigenome during differentiation can point to genomic features that play key roles in the differentiation process [1] .
In virtually every cell type and organ system, normal differentiation and development is associated with characteristic changes in epigenetic patterns, which allow for the establishment and stable maintenance of a wide variety of cellular phenotypes without alterations to the genome (recently reviewed in [2] ). In terms of disease, epigenetic aberrations have been shown to result in developmental abnormalities, degenerative disease and cancer (also reviewed in [3] [4] [5] [6] ) [7] [8] [9] . In the most inclusive definition, epigenetics is the study of mechanisms that change gene activity without altering the DNA sequence, and thereby include not only DNA methylation and histone modifications, but also transcription factors and noncoding RNAs. In fact, there has been rather extensive debate regard-
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ing the definition of epigenetics, and in particular how heritable a mark must be to be considered epigenetic. Recent advances in the fields of cell biology and epigenomics have demonstrated that many epigenomic marks are less stable than previously believed, and that certain sequences of epigenetic events that were once thought to be irreversible (e.g., progression from pluripotent or multipotent stem cells to fully differentiated mature cell types) can in fact be reversed using cellular reprogramming techniques [10] [11] [12] .
Human pluripotent stem cells (PSCs) have tremendous potential for in vitro modeling of development and disease due to their self-renewal properties and their ability to differentiate into all cell lineages in the body. Human embryonic stem cells (hESCs) [13] , which are derived from the inner cell mass of blastocyst-stage preimplantation embryos, are considered the gold standard PSCs. Two other types of PSCs have been produced: induced pluripotent stem cells (iPSCs), which are generated from somatic cells by overexpression of a small number of reprogramming factors [10, 11] ; and somatic cell nuclear transfer ESCs (SCNT-ESCs), which are derived from embryos resulting from the introduction of a somatic cell nucleus into an enucleated oocyte [14] . In the blastocyst, the pluripotent state represented by the cells in the inner cell mass is transient. In vitro however, the pluripotent state as represented by PSCs can be artificially maintained for an indefinite period of time. This greatly increases the utility of the cells, but also makes them susceptible to genomic and epigenomic aberrations [15] [16] [17] [18] . It is therefore important to assess how such aberrations may impact the efficacy of PSCs in accurately modeling development and disease, and serving as sources of material for cell therapy.
The dynamic interplay between the transcriptome and epigenome warrants implementation of genomewide approaches and high-throughput technologies to identify and characterize mechanisms and molecular factors that regulate genome function during development, lineage-specification and disease pathology. In this article, we describe the current genome-wide profiling platforms and large-scale consortiums that have utilized these technologies to understand the epigenome, and also review the existing literature with an emphasis on publications that have utilized genome-wide approaches to describe: the epigenetic landscape of pluripotency and cellular differentiation, as modeled by undifferentiated and differentiated PSCs; differences among different types of PSCs; differences between in vitro maintained ESCs and cells in the developing embryo; and the dynamic changes in the epigenome that occur during reprogramming. We will focus on two of the most well-studied epigenetic mechanisms: DNA methylation and histone modifications, and will only briefly touch on noncoding RNAs (as we have recently written a review on the role of miRNAs in pluripotency [19] ).
The epigenome in mammalian development DNA methylation is an essential mechanism that has been shown to play a key role in both gene regulation in the context of genomic imprinting, X chromosome inactivation and regulation of some autosomal nonimprinted genes and preservation of genomic stability. It is becoming increasingly clear that DNA methylation at different genomic loci is regulated by several different mechanisms and involves the interplay between DNA methyltransferases (DNMTs), DNA dioxygenases, cytidine deaminases and various DNA-binding proteins. These processes are particularly active during early development, and evidence is growing that they are important for the establishment and stabilization of the pluripotent state.
DNMT1 is the primary maintenance DNA methyltransferase, and is responsible for converting the hemi-methylated CpG dinucleotides that are generated during DNA synthesis into fully methylated CpGs. DNMT3A and DNMT3B are de novo DNA methyltransferases, which can establish new DNA methylation at completely unmethylated CpG sites, as well as methylate cytosines located at non-CpG sites. Maintenance of DNA methyltranferase activity has been shown to be critical for development. Mice with homozygous mutations in Dnmt1, resulting in partial to complete loss of Dnmt1 function, were embryonic lethal by midgestation and were associated with imprinting defects [20] . Mouse Dnmt3a knockouts are postnatal lethal and associated with imprinting defects [21] , while Dnmt3b knockouts are lethal in the late embryonic period and showed defects in methylation of endogenous viral and satellite DNA sequences [21] . Dnmt3a/b double knockouts have a more severe phenotype, dying at midgestation, indicating that there is partial redundancy between these two DNA methyltransferases [20, 22] .
It has been shown that the absence of all three DNA methyltransferases in mouse TKO ESCs results in near-total demethylation of genomic DNA, but does not affect self-renewal, expression of pluripotency markers or global chromatin structure [23] . However, in contrast to wild-type mouse ESCs or mouse ESCs lacking Dnmt1 only, the mouse TKO ESCs do not stably differentiate when induced to form embryoid bodies, and readily revert to a pluripotent phenotype when returned to culture conditions favorable for undifferentiated PSCs [24] . These results indicate that DNA methylation is dispensable for maintenance of the undifferentiated state, but is necessary for lineage commitment.
Differential methylation of CpG sites in CpG islands [25] and those distributed more sparsely across the genome is established during development by global demethylation followed by selective remethylation. Following widespread erasure of DNA methylation marks during early development, de novo DNMTs are involved in global remethylation of the genome. During this process, most CpG islands are excluded from DNA methylation [26] . It has been shown that the primary mechanism for protection of CpG islands from methylation is through proximal cis-regulatory regions, such as transcription factor binding sites [26, 27] . R-loops also protect CpG islands from methylation. R-loops result from the fact that CpG islands are skewed toward having one strand of the double helix rich in guanine, and the complementary strand rich in cytosine (GC skew). During transcription, the nascent G-rich RNA segments bind to the C-rich DNA strand, which forces the G-rich DNA strand to form a loop, thus protecting these sequences from the de novo DNA methyltransferases [28] .
Early mammalian development, including the period from gametogenesis through the specification of the three major cell lineages, is marked by several major epigenetic changes -imprinting and X chromosome inactivation being the most heavily studied [1] . Studies in this area have been challenging due to the limited numbers of cells in the early embryo and the differences among species, which prevent generalizations from model organisms to the human system [29, 30] .
Imprinting refers to the inactivation of one of the two alleles at a given genomic locus in a parent-of-originspecific manner, and is established during gametogenesis. Following fertilization, human zygotes undergo a wave of global DNA demethylation, but DNA methylation status at imprinting control regions (ICRs) remains unchanged, preserving parental allele-specific DNA methylation at these sites and consequently parent-of-origin-specific imprinted gene expression [31] . Imprinted regions are characterized by expression of nearby long noncoding RNAs (lncRNAs) [32] , specific histone modifications [33, 34] , and DNA methylation. Aberrant imprinting in humans has been correlated with several developmental diseases, such as BeckwithWiedemann, Prader-Willi and Angelman syndromes, as well as malignancies, such as Wilms' tumor [35] [36] [37] . Most imprinted genes are found in clusters, with members of a cluster regulated simultaneously by a common ICR [38] . ICRs were traditionally thought to be established and maintained through DNA methylation, but recent reports suggest that other epigenetic modifiers are involved [39] . These reports include histone modification features that may signal the specificity of imprint acquisition during spermatogenesis and may be critical for establishing the DNA methylation imprints during oogenesis [33, 34] .
How imprinted loci retain their parent-of-origin specific gene expression during development has yet to be fully elucidated. In murine models, it appears that the protection and maintenance of imprinted marks during global demethylation events in pre-implantation embryos, and in subsequent differentiation events in development, depends on an epigenetic modifier complex formed by ZFP57 and TRIM28 [40] [41] [42] . The zinc-finger protein ZFP57 recognizes and binds to the methylated hexanucleotide motif (TGCCGC) in ICRs, and recruits TRIM28 and the DNMT3s to maintain DNA methylation and heterochromatinization at many imprinted domains across the genome [43] . How accurately the ZFP57/TRIM28/DNMT3 complex prevents demethylation of ICRs during demethylation events, and if other components or complexes are involved in the protection and maintenance of imprinting, has yet to be determined. Mouse models have also shown that the PGC7 complex has a role in protecting the maternal sequences from early development demethylation [44] . Interestingly, PGC7 was also shown to interact with histone modification factor, H3K9me2, highlighting cooperative interplay between the methylome and histone modifications to prevent demethylation [45] . How DNA methylation is initially established at ICRs remains an outstanding question in the field.
Another level of epigenetic control of gene expression is through X chromosome inactivation (XCI). XCI results in the transcriptional silencing of one of the two X chromosomes in female cells, thereby balancing the gene dosage from the X chromosome between female and male cells. The mechanism by which one of the two X chromosomes is inactivated involves extensive changes in histone modifications, DNA methylation changes and several noncoding RNAs [38, 46] . The most well characterized of these critical noncoding RNAs is X-inactive specific transcript (XIST), which is expressed from one of the two X chromosomes in female cells. XCI regulation by the XIST transcript is a paradigm for epigenetic silencing mediated by noncoding RNAs. XIST acts in cis to coat the X chromosome from which it is expressed, mediating the initiation and maintenance of XCI by recruiting histone-modifying complexes and by inducing nuclear reorganization [47] . In the mouse, XCI is initiated during the pre-implantation period with silencing of the paternal X chromosome. The paternal X chromosome is then reactivated in the ICM at the blastocyst stage resulting in two active X chromosomes. In the trophoectoderm (TE) lineage however, paternally imprinted XCI is maintained. During gastrulation, random XCI in embryonic cells is initiated by XIST. Although it is believed future science group that XIST works similarly in mouse and human cells, the mechanisms controlling its expression and the developmental stage at which it is expressed is fundamentally different in murine and human development (recently reviewed in [48, 49] ). Recent evidence points to potential differences between the primate and murine XCI pathway, where the primate TE lineage does not display imprinted paternal XCI [50] .
While XCI is a complex process that is still incompletely understood, application of high-throughput sequencing technology is beginning to yield insights and challenge current paradigms. Using allele-specific sequencing of mouse trophoblast stem cells, Calabrese et al. discovered DNAse1 hypersensitive sites on the inactive X chromosome, despite the lack of other markers of transcriptional activity [51] . Additionally, the small fraction of genes on the X chromosome (∼15%) that escape X inactivation were found to be located both inside and outside of the domain coated by XIST. These results suggest that there are as-yet undiscovered site-specific regulatory elements that act on the inactive X chromosome.
The epigenomic landscape of human PSCs
Epigenomic profiling of human PSCs has been used to address several important questions. First, are human PSCs epigenetically stable? Second, are there differences in the epigenetic stability of human PSCs derived or cultured under different conditions, and do any observed differences correlate with the pluripotency of the cells? Third, what epigenetic changes occur during reprogramming and differentiation of human PSCs (and do they represent the changes that occur during normal cellular differentiation in vivo)?
Aberrant DNA methylation at imprinted loci in hESCs and human iPSCs (hiPSCs) has recently been shown to be both widespread and variable [52, 53] . Comprehensive DNA methylation profiling of large numbers of PSC lines revealed that hypermethylation of the PEG3, MEG3 and H19 loci were found to be particularly prevalent and associated with downregulation of gene expression in human PSC lines [52] , in contrast to earlier studies using targeted gene expression assays on smaller numbers of cell lines, which reported stable monoallelic expression for these genes in hPSCs [54] [55] [56] . It is unclear whether or not in vitro culture conditions are to blame for the observed imprinting aberrations, as they were evident even in low passage hESCs [53] . Another study showed that the reprogramming of somatic cells to pluripotency did not affect the stability of the vast majority of differentially methylated regions (DMRs), which are regions that are differentially methylated between different cell types and are often associated with regulatory regions, such as enhancers [57] . Loss of imprinting in reprogrammed hiPSCs at the PEG3, DIRAS3 and ZDBF2 loci was also reported, but only the aberrant methylation of ZDBF2 could be attributed to reprogramming, as the other two genes also exhibited a loss of imprinting in the parental somatic cells [57] . For hPSCs displaying aberrations at imprinted regions, differentiation did not result in correction of the aberrations, or in appearance of new aberrations [52, 53] .
A majority of human female ESCs show non-random XCI [58] . Female hESCs can be categorized into three different classes based on their XIST expression [59] . Class I hESCs express low levels of XIST, have two active X chromosomes in the pluripotent state and undergo random XCI upon differentiation; this state has been associated with naive pluripotency [52, [60] [61] [62] . Class II hESCs express XIST at levels similar to those of differentiated cells, and are in the XaXi state (Xa: active; Xi: inactive) with the inactive X being coated by XIST; most reported female hPSCs fall into this class [63] [64] [65] [66] [67] . Class III hESCs are frequently in the XaXi state, but have lost XIST expression, so the inactive X chromosome lacks XIST coating. Unlike in Class I cells, XIST expression in Class III cells remains off following differentiation [68] . Currently, a widely accepted model is that newly derived human ESCs start in Class I and contain two active X chromosomes, but due to suboptimal in vitro culture conditions, they undergo XCI to become Class II, and some lines later lose XIST expression and fall into Class III [60] . However, experiments in mammalian pre-implantation embryos indicate that the process of XCI in mice and humans is highly divergent, and thus bring this model into question. Unlike in mouse embryos, XIST is expressed in the majority of the cells in the human embryo starting at morula stage, and initially coats both X chromosomes in female cells, even in inner cell mass cells [29] .
Several studies detailing the XCI of iPSCs in reprogrammed female human cells have recently been published, with sometimes conflicting results. Some groups have reported that reprogramming does not result in the reactivation of Xi, and that iPSCs receive the Xi from their parent somatic cell [66, 67] , while others have shown that reprogramming results in the reactivation of Xi [61, [69] [70] . Furthermore, several recent reports show that hiPSCs are often initially XaXi with XIST expression present, but quickly lose their XIST expression in culture [52, 58, 66, 67, [70] [71] [72] . When XIST expression is lost, it appears that a subset of Xi-linked genes is activated and this activation is accompanied by the loss of DNA methylation in multiple regions of the X chromosome in a patchy and progressive fashion [52, 72] . It has been suggested that certain culture condifuture science group tions promote the XaXa state. Lengner et al. showed that hypoxia could be used to derive hESCs that have not undergone XCI [60] . Tomoda et al. reported that reprogramming on LIF-secreting feeder cells often resulted in XaXa hiPSC lines, and that the addition of LIF to the medium for XaXi hiPSCs resulted in reactivation to the XaXa state [70] . Other experiments indicate that HDAC inhibitors [73] or other small molecules [62] may promote conversion of the XaXi state to the XaXa state. Recently, a lncRNA, XACT, that coats the active X chromosome has been identified in humans [74] . It appears as if this lncRNA is not present in mice or in differentiated cell types, and the authors speculate that XACT may be involved in the initiation of XCI in humans.
Although evidence is mounting that reprogramming/derivation methods and culture conditions can influence the XCI status of hPSCs, robust and reproducible methods for control of hPSC XCI have not yet been established. In addition, what the 'normal' state of X chromosome inactivation is in the pluripotent cells in the human embryo still remains to be completely understood. In the meantime, it has been noted that for modeling of diseases caused by X-linked mutations, it is important to monitor the XCI status of the hPSCs over time [52, 72] .
Soon after iPSC technology was first developed, the question of whether there are systematic differences between iPSCs and hESCs arose. Since the histories of the nuclear genomes of these two types of hPSCs are quite different, it is not unreasonable to think that there might be significant differences in their epigenomes. As will be discussed below, several studies have addressed this issue, but we wish to point out that a common limitation to the existing literature is that sets of well-matched cell lines do not yet exist, for which adequate numbers of hESC and hiPSCs have been genetically matched for potentially confounding variables, such as oxygen tension, media type (including growth factors and small molecule additives), substrate (including feeder cells and type of extracellular matrix), and passage method. The recent success in generation of human SCNT-ESCs has generated further speculation as the history of the nuclear genomes of these cells have similarities with both iPSCs (i.e., being derived from the nucleus of a somatic cell) and ESCs (i.e., being reprogrammed by the cytoplasm of an oocyte, and undergoing preimplantation embryo development from the cleavage to blastocyst stages). In particular, it will be interesting to uncover the magnitude and types of differences between SCNT-ESCs and hESCs, as these may represent the epigenomic changes that take place during gametogenesis and fertilization.
The epigenomics of reprogramming & differentiation
It has been suggested that reprogramming of somatic cells to the pluripotent state occurs in two phases. The first phase involves changes in gene expression and remodeling of histone marks, and the second phase results in the consolidation of pluripotency through changes in DNA methylation and histone modifications [75, 76] . Two studies support the notion that remodeling of DNA methylation is the rate-limiting step in the process of complete reprogramming [77, 78] . First, the Blau laboratory reported that activation of the OCT4 and NANOG genes occurred much more rapidly during reprogramming accomplished by fusion of somatic cells with PSCs (∼1 day) than by the overexpression of standard reprogramming factors (∼2 weeks), and that AID was required for this process [77] . Second, 'lifting' of the repression at the NANOG promoter by the methyl DNA-binding protein MDB2 was necessary to attain the fully reprogrammed state; paradoxically, MDB2 was shown to be subject to repression by the pluripotency-associated miRNA miR-302 [78] . In terms of histone modifications, a recent genome-wide analysis of the binding sites of pluripotency factors, POU5F1/ OCT4, SOX2, KLF4 and c-MYC (OSKM) was conducted during the first 48 h of reprogramming [79] . Genomic regions lacking OSKM binding were identified as loci that were potentially bound by endogenous factors that were impediments to reprogramming. Interestingly, it was found that the repressive H3K9me3 mark was found to be associated with these regions lacking OSKM binding, and was therefore inferred to be an impeding factor [79] .
It has been observed that global DNA methylation is higher in hPSCs than in differentiated human cells [9, 52, 57] . This is true not only at CpG sites, but also for cytosines at non-CpG sites [9, 57] . In fact, consistent with an earlier paper reporting non-CpG methylation in mouse ESCs [80] more recent reports have shown that non-CpG methylation was markedly more prevalent in hESCs than somatic cells, accounting for up to 20% of DNA methylation in hESCs [9, 57] . It has also been shown that loci that are specifically hypomethylated in certain tissue types are uniformly hypermethylated in hPSCs, and that a subset of these sites become hypomethylated upon in vitro differentiation to the relevant lineage [52] .
Histone modification patterns can affect the developmental potential of hPSCs. One important histone modification feature among PSCs is bivalent domains. Bivalent domains are marked by poised/active (H3K4me3) and repressive marks (H3K27me3), and are typically associated with transcription factors and genes associated with development and lineage specification [81, 82] . This is thought to provide rapid access to lineage specifuture science group fication factors during differentiation through the loss of H3K27me3. Changes in histone modifications are generally thought to precede DNA methylation during cellular differentiation, as they are more dynamically regulated during differentiation [83] . ESCs have a more open chromatin configuration with abundant active chromatin marks such as H3K4me3 and fewer H3K9 trimethylation regions compared to differentiated cells [84, 85] . Other chromatin modifications important for development include histone H3 at lysine 4, 9 and 27 [86] .
Chromatin modifications at enhancers are another prevalent feature of differentiation and cell lineage decisions. Beyond the H3K4me3 and H3K27me3 marks, which are predominantly found at promoters, the active enhancer marks, H3K4me1 and H3K27ac, are of increasing interest. Several studies identified the presence of over 7000 enhancers in hESC that can be grouped as either active or poised enhancers and can be distinguished by the H3K27ac mark [87, 88] . Recently, it was shown that approximately <1% of enhancers form 50 kb domains, known as 'super-enhancers', which are marked by epigenetic regulatory features such as the Mediator coactivator complex [89] , H3K4me1 and H3K27ac. These super-enhancers are frequently associated with transcription factors that have been identified as critical regulators of cell fate [90] . These results highlight an important interaction between transcription factors and global chromatin engagement.
Several studies in a variety of biological systems have suggested that regulation of gene expression by DNA methylation and histone modifications is a complex combinatorial process [91] , wherein some histone marks are well-correlated with DNA methylation, while others regulate sets of genes that do not appear to be regulated by DNA methylation [92] , and yet others show complex relationships that seem to be contextdependent. One of the most interesting interactions is between DNA methylation and the H3K27me3 mark. As mentioned above, in mouse ESCs, it was shown that repressive H3K27me3 marks were frequently colocalized with activating H3K4me3 marks, resulting in a 'poised' bivalent state [83] , which resolves into the fully active or fully repressed state upon differentiation [82, 93] . In HeLa cells, the polycomb group protein EZH2, which catalyzes the methylation of H3K27, physically associates with DNA methyltransferases and promotes DNA methylation [94] . Furthermore, studies in mouse ESCs showed that DNA methylation prevents the placement of H3K27me3 marks [95, 96] , and recently, a study was published that demonstrated a correlation between 5-hydroxymethylcytosine and H3K27me3 in a variety of cell types [97] . Taken together, these studies suggest that there may be a temporal hierarchy, in which the polycomb repressive complex first places the repressive H3K27me3 mark, and then recruits DNA methyltransferases to solidify repression of gene expression. In this repressed state, DNA methylation inhibits the placement of new H3K27me3 marks. However, conversion of 5-methylcytosine to 5-hydroxymethylcytosine appears to again allow the placement of H3K27me3 marks.
Two recent studies have reported on integrative analysis of DNA methylation, histone modification and transcriptome data in hESCs in the undifferentiated state and during early in vitro differentiation toward the three germ lineages [98, 99] . In the Gifford et al. study, it was observed that in hESCs, some CpG-poor regions of the genome switched from a highly methylated state (highly methylated regions [HMRs]) to high enrichment for H3K27me3 when the cells were differentiated to definitive endoderm, but remained HMRs during early differentiation to ectoderm or mesoderm [99] . This suggests that some genomic regions that are activated upon differentiation go from a highly DNA methylated state to a H3K27me3 state, the complement of the findings in mouse ESCs discussed above which showed that regions of the genome that became repressed with differentiation were first marked by H3K27me3, and then switched to a DNA methylation state. The same authors also reported that these regions frequently included binding sites for the endodermassociated transcription factor FOXA2, suggesting that certain transcription factors may be able to bind to methylated DNA and stimulate demethylation [99] .
In contrast to the sequential role for the H3K27me3 marks and DNA methylation in gene repression of the same genomic loci suggested by the earlier studies in mouse ESCs and the Gifford et al. study discussed above [99] , the Xie et al. study found that H3K27me3 and DNA methylation appear to repress different genomic loci [98] . Namely, genes that were differentially expressed during early lineage specification had promoters that were CG-rich and were repressed by H3K27me3, while genes that were differentially expressed at later stages of differentiation had promoters that were CG-poor and were controlled by DNA methylation. These results support the notion that histone chromatin marks are the predominant repressive marks in open chromatin, mediating transcriptional repression in the rapidly changing cellular milieu during early lineage commitment, while DNA methylation mediates a more stable form of repression, and therefore would be better suited for setting long lasting marks necessary for stable maintenance of the cellular phenotypes produced by late stage differentiation. It is important to note that in these studies, the characterization of genomic loci involved in early lineage commitment was performed by studying hESCs undergoing in vitro differentiation, while the identification of future science group loci involved in later differentiation was performed using data from tissue samples. Although in vitro differentiation of hESCs appears to recapitulate in vivo differentiation in many respects, including sequential changes in cellular morphology and expression of key markers, it should be kept in mind that it has not been rigorously verified that they correspond in all respects.
In addition to interrogating histone modifications, the Gifford et al. study also used ChIP-seq to characterize the binding patterns of the pluripotency-associated transcription factors POU5F1, SOX2, and NANOG [99] . The combinatorial binding patterns for these transcription factors were assessed, revealing that sites bound by POU5F1 alone were primarily associated with promoter regions, in contrast to sites bound by all three factors, SOX2 only or NANOG only, which tended to be in intergenic or intragenic regions. Integrating the transcription factor and histone modification data revealed that dual POU5F1/H3K4me1 occupancy in the undifferentiated state was associated with HMRs regions. The study by Gifford et al. also discovered an enrichment for predicted binding sites for a number of early lineage-specific transcription factors in regions bound by different combinations of POU5F1, SOX2, NANOG and activating histone marks in hESCs in the undifferentiated and early differentiated states [99] . This finding suggests that pluripotency-associated transcription factors might 'set up' pluripotent cells for differentiation by ensuring that certain genomic regions are permissive for the proper epigenetic modifications involved in differentiation, or even play a direct role in early differentiation of certain lineages.
In another approach, a recent manuscript from the Sander laboratory used integrative analysis of histone modifications (H3K4me3 and H3K27me3) and transcriptome data to compare the later stages of differentiation in vivo and in vitro [100] . In this study, hESCs were subjected to in vitro lineage commitment to the pancreatic endoderm stage, and then either transplanted into mice or maintained in vitro for further differentiation. The resulting two populations of cells were analyzed by ChIP-seq and RNA-seq, and compared to human islets. Undifferentiated hPSCs were found to have bivalent marks (H3K4me3 and H3K27me3) for definitive endoderm, pancreatic endoderm and endocrine regulators. The regulators of definitive endoderm were appropriately activated during in vitro differentiation at the definitive endoderm stage and repressed at the pancreatic endoderm stage, and these modulations in transcription were mirrored by the appropriate loss of the H3K27me3 mark. Moreover, regulators of pancreatic endoderm were also appropriately activated during in vitro differentiation at the pancreatic endoderm stage, with the corresponding loss of H3K27me3. However, the proper derepression of late endocrine markers occurred only in the cells transplanted into mice for in vivo maturation; in the cells maintained in vitro, late endocrine markers were poorly expressed, and their promoters remained in the bivalent state. From these results, the authors concluded that lack of proper histone remodeling is at least in part responsible for the dysfunction of in vitro differentiated pancreatic endocrine cells [100] .
Genome-wide profiling methods & epigenome maps
Advances in high-throughput profiling methods, such as microarrays and next-generation sequencing (NGS) greatly advanced our understanding of the epigenome. NGS platforms have provided the capacity to tackle the complexity and multidimensionality of the epigenome. Several methods have been adopted to profile the DNA methylation and histone modification status of pluripotent cells and differentiated cells. We will briefly describe the most commonly used high-throughput methods (reviewed in detail in [101] ).
DNA methylation profiling involves bisulfite treatment of DNA, which results in the conversion of unmethylated cytosine residues to uracil residues, while methylated cytosines are protected from bisulfite conversion, and remain as cytosines. Following PCR, the converted cytosines become thymidines. The bisulfite-treated DNA can then be analyzed on microarrays, such as the Infinium HumanMethylation450K BeadChip (Illumina), designed to detect the presence of a cytosine versus thymidine at selected positions in the genome or subjected to NGS to directly read the presence of a cytosine versus thymidine, either in selected regions of the genome (e.g., using reduced representation bisulfite sequencing (RRBS) [102] or across the entire genome [103] . One of the major limitations of the standard microarray or bisulfite sequencing methods is that they do not distinguish between 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) [104, 105] , the latter being an intermediate during DNA demethylation and shown to mark regulatory regions in fetal brain cells [106] and enriched at enhancers in ESCs [107] [108] [109] . However, a new method, called oxidative bisulfite sequencing (oxBS-seq), when compared to standard bisulfite sequencing of the same sample, does allow distinguishing betweenallows one to distinguish between unmethylated, methylated and hydroxymethylated cytosines [110] . Comparisons between genomewide DNA methylation profiling technologies have been reviewed in detail elsewhere [111, 112] and summarized in Figure 1 . As an adjunctive approach, RNA-seq or allele-specific qRT-PCR can be used to detect allelespecific expression and thereby infer the DNA methylation status of loci subject to imprinting or XCI [51] .
future science group
Chromatin immunoprecipitation (ChIP) is the primary method used to detect physical interactions between DNA sequences and proteins. Using antibodies specific for the modified histone or transcription factor of interest, the genomic regions bound by the selected protein are isolated and identified by tiling array (ChIP-chip [82, 113] ) or NGS analysis. One of the major advantages of ChIP-seq is the ability to profile and detect repetitive sequences. Other derivations of the technology include ChIP-PET, where pair-ended reads are obtained for the ChiP fragments [114] . Integrative, epigenomic profiling approaches such as the combination of ChIP and bisulfite sequencing (ChIP-BS-seq, BisChIP-seq) [96, 115] will enable interrogation of the same molecule and yield insights into the crosstalk between DNA methylation and histone modifications.
Large-scale epigenetic project initiatives have capitalized on NGS technologies to create and compile genome-wide, epigenome maps of cell types and tissues important in development and diseases [116] . The Roadmap Epigenomics [117] and the Encyclopedia of DNA Elements (ENCODE) [118] consortiums are both NIHfunded projects. ENCODE represents an international consortium of research groups with the primary aim to discover and identify functional and regulatory elements in the genome. In humans alone, ENCODE hosts over 4000 individual datasets from a wide variety of platforms on 147 cell lines. The goal of the Roadmap Epigenomics Project is to create reference maps of normal and primary cell types and to host these datasets in Human Epigenome Atlas public database. The epigenome in pluripotency & differentiation Review GSE35140 CTCF binding sites in mouse brain were compared to ESCs and liver, and analyzed in an allele-specific manner
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BeadChip (HumanMethylati on27_270596_v.1.2), Illumina HumanMethylation450 BeadChip (HumanMethylation450_15017482)
Homo sapiens [52] These genome-wide datasets are often integrative and multidimensional, involving profiling of epigenetic features such as histone modifications, DNA methylation and enhancers. Gene expression data complements the epigenetic feature in question and the results of these studies often demonstrate crosstalk between the epigenome and transcriptome. GSM429321-23, GSM432685-92, GSM438361-64, GSE17917, GSE18292 and GSE16256; see [122] First genome-wide, maps of methylated cytosines in both hESCs and fetal fibroblasts, along with comparative analysis of messenger RNA and small RNA components of the transcriptome, several histone modifications, and sites of DNA-protein interaction for several key Homo sapiens [57] Not available Female (hESCs) exhibit variation (0-100%) for XCI markers, including XIST RNA expression and enrichment of histone H3 lysine 27 trimethylation (H3K27me3) on the inactive X chromosome (Xi). Female hESCs have already completed XCI during the process of derivation and/ or propagation SNP-Array;
GE; meDIPChip Not available
Homo sapiens [58] GSE20937 Describe the establishment of XaXa hESCs derived under physiological oxygen concentrations GE Agilent-014850 Whole Human
Genome Microarray 4×44K G4112F
Homo sapiens [60] GSE21037 Rett syndrome iPSCs are able to undergo X inactivation and generate functional neurons
Human Gene 1.0 ST Array
Homo sapiens [61] GSE21222 Convert conventional hESCs into a more immature state that extensively shares defining features with pluripotent mouse ESCs. This was achieved by ectopic induction of Oct4, Klf4, and Klf2 factors combined with LIF and inhibitors of GSK3β and MAPK (ERK1/2) pathway
Human Genome U133 Plus 2.0 Array
Homo sapiens [62] GSE22246 Reprogramming of female fibroblasts does not reactivate Xi, however the Xi undergoes chromatin changes. This nonrandom pattern of X chromosome inactivation in female hiPSCs is maintained upon differentiation
Homo sapiens [67] GSE34527 X-inactivation status in female hiPSC lines depends on derivation conditions GE Agilent-014850 Whole Human
Homo sapiens [70] GSE36233 X-inactivation markers can be used to separate hiPSC lines into distinct epigenetic classes
GE Not available
Homo sapiens [71] GSE15112 
GSE39757
Discovery of a long noncoding RNA, XACT, which is expressed from and coats the active X chromosome specifically in hPSCs
RNA-Seq Illumina HiSeq 2000
Homo sapiens [74] GSE46700 Compare the ability of cells lacking AID to reprogram from a differentiated murine cell type to an induced pluripotent stem cell. AID removes epigenetic memory to stabilize the pluripotent state RRBS; RNASeq Illumina HiSeq 2000
Mus musculus [75] Not available Defined intermediate cell populations poised to become iPSCs. Induced pluripotency elicits two transcriptional waves, which are driven by c-Myc/Klf4 (first wave) and Oct4/Sox2/Klf4 (second wave). The establishment of bivalent domains occurs gradually after the first wave, whereas changes in DNA methylation take place after the second wave when cells acquire stable pluripotency
ChIP-Seq, miRNA array Not available
Mus musculus [76] GSE36570 A map of Oct4, Sox2, Klf4, and c-Myc (O, S, K and M) on the human genome during the first 48 h of reprogramming fibroblasts to pluripotency
ChIP-Seq Illumina Genome Analyzer IIx
Homo sapiens [79] GSE12646 H3K4me1, H3K9me1 and H3K27me1 associate with enhancers of differentiation genes prior to their activation and correlate with basal Homo sapiens [81] GSE8024, GSE12241; see [123] Genome-wide chromatin-state maps of mouse ESCs, neural progenitor cells and embryonic fibroblasts. Define three categories of promoters in ESCs, including bivalent promoters; and demonstrate the use of ChIP for genome-wide annotation active transposable elements, imprinting control regions and allele-specific transcription ChIP-Seq Affymetrix Mouse Genome 430 2.0
Array Illumina Genome Analyzer
Mus musculus [82] See [124] Bivalent domains silence developmental genes in ESCs while keeping them poised for activation Homo sapiens [99] E-MTAB-1086 Transcriptome and select chromatin modifications at defined stages during pancreatic endocrine differentiation of hESCs ChIP-Seq; RNA-Seq Illumina Genome Analyzer IIx
Homo sapiens [100] SRA000206; see [125] Genome-wide histone modification maps of 20 histone lysine and arginine methylations as well as histone variant H2A.Z, RNA polymerase II, and the insulator-binding protein CTCF across the human genome
ChIP-Seq Not available
Homo sapiens [113] These genome-wide datasets are often integrative and multidimensional, involving profiling of epigenetic features such as histone modifications, DNA methylation and enhancers. datasets of PSC and differentiated lines. The success of these initiatives have spurred additional projects, such as the latest consortium, BLUEPRINT, an European initiative aimed to generate 100 reference epigenomes from hematopoietic cells and their malignant leukemic counterparts. The epigenome maps from these initiatives and other sources have immensely improved our understanding of the epigenetic regulatory mechanism during pluripotency and its dynamic use during differentiation (Table 1) as described throughout this review. The ENCODE [119] and Roadmap Epigenomics [120] datasets are available online and is also hosted at the UCSC Genome Browser for visualization [121] .
Conclusion
The studies discussed here have demonstrated that characterization of early in vitro differentiation of hPSCs using genome-wide transcriptome and epigenome datasets can reveal patterns and associations that suggest a complex combinatorial mechanism for epigenomic regulation of early differentiation. It is clear that further work is necessary to verify and determine the functional consequences of the interactions between general epigenomic marks (i.e., DNA methylation and histone modifications), pluripotencyassociated transcription factors and lineage-specific transcription factors suggested by these studies. Moreover, as methods for differentiation of hPSCs to more mature cell types are developed and optimized, it will be intriguing to see whether the same patterns of epigenomic regulation will apply, or whether distinct mechanisms will be uncovered.
Future perspective
As noted above, it still remains to be determined which type of hPSC best represents the pluripotent stem cells in the human embryo, and how closely in vitro differentiation of hPSCs resembles the bona fide cellular differentiation that occurs during development. For some applications, such as highthroughput screening for cell type-specific drug toxicity, modeling of certain diseases, or cell therapy, it may not be critical for hPSC-derived cells to be perfect epigenomic matches of the corresponding tissue-derived cell, as long as the hPSC-derived cells possess specific phenotypic properties (e.g., the ability to secrete insulin in a glucose-dependent manner for cell therapy for Type 1 diabetes mellitus). However, for accurate modeling of development and developmental or degenerative diseases, discrepancies between in vivo and in vitro differentiation may be problematic. Although technically challenging, it is important that studies delineating the dynamic role of the epigenome in mammalian development continue to be performed. No writing assistance was utilized in the production of this manuscript.
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Executive summary
The epigenome in mammalian development
• Mammalian development is tightly regulated by epigenetic events and can be studied using pluripotent stem cells (PSCs), including human embryonic stem cells and induced PSCs. Although PSCs can be valuable in vitro models to study the differentiation process, care must be taken due to epigenetic aberrations, such as instability of X chromosome inactivation and hypo-or hyper-methylation of imprinted loci, which can be induced during derivation and long-term culture.
The epigenomics of reprogramming & differentiation
• Recent studies have shown that regulation of gene expression by DNA methylation and histone modifications is an intricate combinatorial process in which some histone marks are well-correlated (or anti-correlated) with DNA methylation, others regulate sets of genes that do not appear to be regulated by DNA methylation, and yet others show complex relationships with DNA methylation that seem to be context-dependent.
Genome-wide profiling methods & epigenome maps
• Advances in high-throughput profiling methods, such as microarrays and next-generation sequencing (NGS), have greatly advanced our understanding of the epigenome. More recently NGS platforms have provided the capacity to tackle the complexity and multidimensionality of the epigenome. Methods that are becoming increasingly popular for profiling of the DNA methylation and histone modification status of pluripotent cells and differentiated cells include reduced representation and whole-genome bisulfite sequencing and chromatin immunoprecipitation profiling on microarrays and high-throughput sequencing.
